{"id":"abp-654","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypocalcemia"},{"rate":null,"effect":"Osteonecrosis of the jaw"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL5952110","moleculeType":null,"molecularWeight":"586.79"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABP 654 binds to RANKL, a key cytokine in the RANK/RANKL/OPG pathway that drives osteoclast differentiation and activation. By neutralizing RANKL, the drug reduces bone resorption and is being developed for conditions characterized by excessive bone loss or osteoclast-mediated pathology. This mechanism is similar to denosumab, an established RANKL inhibitor.","oneSentence":"ABP 654 is a monoclonal antibody that blocks RANKL (receptor activator of nuclear factor kappa-B ligand) to inhibit osteoclast formation and bone resorption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:34.889Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Giant cell tumor of bone"},{"name":"Bone metastases in solid tumors"}]},"trialDetails":[{"nctId":"NCT04607980","phase":"PHASE3","title":"A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-11-11","conditions":"Plaque Psoriasis","enrollment":563},{"nctId":"NCT04761627","phase":"PHASE3","title":"A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-03-24","conditions":"Psoriasis","enrollment":494}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ABP 654","genericName":"ABP 654","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABP 654 is a monoclonal antibody that blocks RANKL (receptor activator of nuclear factor kappa-B ligand) to inhibit osteoclast formation and bone resorption. Used for Giant cell tumor of bone, Bone metastases in solid tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}